Time course of response to paroxetine: Influence of plasma level

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 4, 2007, Pages 892-900

  Gex Fabry, Marianne ^a   Gervasoni, Nicola ^a   Eap, Chin B ^b   Aubry, Jean Michel ^a   Bondolfi, Guido ^a   Bertschy, Gilles ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Hopital de Cery   (Switzerland)

Author keywords

Concentration response relationship; Onset of response; Paroxetine; Plasma concentration

Indexed keywords

PAROXETINE;

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; STEADY STATE; TREATMENT DURATION; TREATMENT WITHDRAWAL;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MIDDLE AGED; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS;

EID: 34247519112     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.02.003     Document Type: Article

References (41)

1. Bagby R.M., Ryder A.G., and Cristi C. Psychosocial and clinical predictors of response to pharmacotherapy for depression. J Psychiatry Neurosci 27 (2002) 250-257
2. Ballesteros J., and Callado L.F. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J Affect Disord 79 (2004) 137-147
3. Baumann P., Hiemke C., Ulrich S., Eckermann G., Gaertner I., Gerlach M., et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37 (2004) 243-265
4. Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol 13 (2003) 57-66
5. Bondolfi G., Aubry J.M., Golaz J., Gex-Fabry M., Gervasoni N., and Bertschy G. A stepwise drug treatment algorithm to obtain complete remission in depression: a Geneva study. Swiss Med Wkly 136 (2006) 78-85
6. Buur Rasmussen B., and Brosen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?. Ther Drug Monit 22 (2000) 143-154
7. Corruble E., and Guelfi J.D. Does increasing dose improve efficacy in patients with poor antidepressant response: a review. Acta Psychiatr Scand 101 (2000) 343-348
8. Danish University Antidepressant Group (DUAG). Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 18 (1990) 289-299
9. Dechant K.L., and Clissold S.P. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 41 (1991) 225-253
10. Driscoll H.C., Basinski J., Mulsant B.H., Butters M.A., Dew M.A., Houck P.R., et al. Late-onset major depression: clinical and treatment-response variability. Int J Geriatr Psychiatry 20 (2005) 661-667
11. Eap C.B., Bouchoux G., Amey M., Cochard N., Savary L., and Baumann P. Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. J Chromatogr Sci 36 (1998) 365-371
12. Feng Y., Pollock B.G., Ferrell R.E., Kimak M.A., Reynolds C.F., and Bies R.R. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br J Clin Pharmacol 61 (2006) 558-569
13. Gelenberg A.J., and Chesen C.L. How fast are antidepressants?. J Clin Psychiatry 61 (2000) 712-721
14. Gex-Fabry M., Balant-Gorgia A.E., Balant L.P., Rudaz S., Veuthey J.L., and Bertschy G. Time course of clinical response to venlafaxine: relevance of plasma level and chirality. Eur J Clin Pharmacol 59 (2004) 883-891
15. Gildengers A.G., Houck P.R., Mulsant B.H., Dew M.A., Aizenstein H.J., Jones B.L., et al. Trajectories of treatment response in late-life depression: psychosocial and clinical correlates. J Clin Psychopharmacol 25 (2005) S8-S13
16. Gilles M., Deuschle M., Kellner S., Shams M., Krumm B., Härtter S., et al. Paroxetine serum concentrations in depressed patients and response to treatment. Pharmacopsychiatry 38 (2005) 118-121
17. Gilmor M.L., Owens M.J., and Nemeroff C.B. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry 159 (2002) 1702-1710
18. Hackett D. Comparing onset of effect of antidepressants: pragmatic considerations on methods and end-points. Eur Psychiatry 13 (1998) 117-123
19. Kato M., Fukuda T., Wakeno M., Fukuda K., Okugawa G., Ikenaga Y., et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 53 (2006) 186-195
20. Katz M.M., Koslow S.H., and Frazer A. Onset of antidepressant activity: reexamining the structure of depression and multiple actions of drugs. Depress Anxiety 4 (1996) 257-267
21. Leon A.C., Blier P., Culpepper L., Gorman J.M., Hirschfeld R.M., Nierenberg A.A., et al. An ideal trial to test differential onset of antidepressant effect. J Clin Psychiatry 62 Suppl 4 (2001) 34-36
22. Lotrich F.E., Bies R.R., Smith G.S., and Pollock B.G. Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies. J Psychopharmacol 20 (2006) 33-40
23. 11C]DASB positron emission tomography study. Am J Psychiatry 161 (2004) 826-835
24. Montgomery S.A., and Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 134 (1979) 382-389
25. Normann C., Horn M., Hummel B., Grunze H., and Walden J. Paroxetine in major depression: correlating plasma concentrations and clinical response. Pharmacopsychiatry 37 (2004) 123-126
26. Owens M.J. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry 65 Suppl 4 (2004) 5-10
27. Pollock B.G., Ferrell R.E., Mulsant B.H., Mazumdar S., Miller M., Sweet R.A., et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23 (2000) 587-590
28. Posternak M.A., and Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry 66 (2005) 148-158
29. Quitkin F.M., Rabkin J.G., Ross D., and Stewart J.W. Identification of true drug response to antidepressants. Use of pattern analysis. Arch Gen Psychiatry 41 (1984) 782-786
30. Reis M., Aberg-Wistedt A., Agren H., Hoglund P., Akerblad A.C., and Bengtsson F. Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Hum Psychopharmacol 19 (2004) 283-291
31. Serretti A., Artioli P., and Quartesan R. Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet Genomics 15 (2005) 61-67
32. Serretti A., Benedetti F., Zanardi R., and Smeraldi E. The influence of serotonin transporter promoter polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 1074-1084
33. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 Suppl 20 (1998) 22-33
34. Szegedi A., Muller M.J., Anghelescu I., Klawe C., Kohnen R., and Benkert O. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 64 (2003) 413-420
35. Tasker T.C., Kaye C.M., Zussman B.D., and Link C.G. Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand 350 (1989) 152-155 Suppl
36. Uchida H., Takeuchi H., Suzuki T., Nomura K., Watanabe K., and Kashima H. Combined treatment with sulpiride and paroxetine for accelerated response in patients with major depressive disorder. J Clin Psychopharmacol 25 (2005) 545-551
37. Ueda M., Hirokane G., Morita S., Okawa M., Watanabe T., Akiyama K., et al. The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 486-491
38. Van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 24 (1993) 203-220
39. Whyte E.M., Dew M.A., Gildengers A., Lenze E.J., Bharucha A., Mulsant B.H., et al. Time course of response to antidepressants in late-life major depression: therapeutic implications. Drugs Aging 21 (2004) 531-554
40. World Health Organization. The ICD-10 classification of mental and behavioural disorders. Diagnostic criteria for research (1993), WHO, Geneva
41. Yoshida K., Takahashi H., Higuchi H., Kamata M., Ito K., Sato K., et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 161 (2004) 1575-1580